Pharmacokinetics of tolfenamic acid in Hawksbill turtles (Eretmochelys imbricata) after single intravenous and intramuscular administration

被引:7
作者
Raweewan, Natsuda [1 ]
Laovechprasit, Weerapong [2 ]
Giorgi, Mario [3 ]
Chomcheun, Thanaphan [2 ]
Klangkaew, Narumol [1 ]
Imsilp, Kanjana [1 ]
Poapolathep, Amnart [1 ]
Poapolathep, Saranya [1 ]
机构
[1] Kasetsart Univ, Dept Pharmacol, Fac Vet Med, Bangkok, Thailand
[2] Eastern Marine & Coastal Resources Res & Dev Ctr, Rayong, Thailand
[3] Univ Pisa, Dept Vet Sci, San Piero A Grado, Italy
关键词
Hawksbill turtle; nonsteroidal anti-inflammatory drugs; pharmacokinetics; tolfenamic acid; PHARMACODYNAMICS; DISPOSITION;
D O I
10.1111/jvp.12823
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To the best of our knowledge, limited pharmacokinetic information to establish suitable therapeutic plans is available for Hawksbill turtles. Therefore, the present study aimed to assess the pharmacokinetic features of tolfenamic acid (TA) in Hawksbill turtles, Eretmochelys imbricata, after single intravenous (i.v.) and intramuscular (i.m.) administration at dosage 4 mg/kg body weight (b.w.). The study (parallel design) used 10 Hawksbill turtles randomly divided into equal groups. Blood samples were collected at assigned times up to 144 hr. The concentrations of TA in plasma were quantified by a validated liquid chromatography tandem mass spectrometry (LC-ESI-MS/MS). The concentration of TA in the experimental turtles with respect to time was pharmacokinetically analyzed using a noncompartment model. The C-max values of TA were 89.33 +/- 6.99 mu g/ml following i.m. administration. The elimination half-life values were 38.92 +/- 6.31 hr and 41.09 +/- 9.32 hr after i.v. and i.m. administration, respectively. The absolute i.m. bioavailability was 94.46%, and the average binding percentage of TA to plasma protein was 31.39%. TA demonstrated a long half-life and high bioavailability following i.m. administration. Therefore, the i.m. administration is recommended for use in clinical practice because it is both easier to perform and provides similar plasma concentrations to the i.v. administration. However, further studies are needed to determine the clinical efficacy of TA for treatment of inflammatory disease after single and multiple dosages.
引用
收藏
页码:135 / 140
页数:6
相关论文
共 33 条
[11]  
Jaussaud P, 1992, Equine Vet J Suppl, P69
[12]   Reptile cardiology: A review of anatomy and physiology, diagnostic approaches, and clinical disease [J].
Kik, MJL ;
Mitchell, MA .
SEMINARS IN AVIAN AND EXOTIC PET MEDICINE, 2005, 14 (01) :52-60
[13]   Pharmacokinetic Behavior of Meloxicam in Loggerhead Sea Turtles (Caretta caretta) after Intramuscular and Intravenous Administration [J].
Lai, Olimpia R. ;
Di Bello, Antonio ;
Soloperto, Simone ;
Freggi, Daniela ;
Marzano, Giacomo ;
Cavaliere, Leonardo ;
Crescenzo, Giuseppe .
JOURNAL OF WILDLIFE DISEASES, 2015, 51 (02) :509-512
[14]   Pharmacokinetics and pharmacodynamics of tolfenamic acid in calves [J].
Landoni, MF ;
Cunningham, FM ;
Lees, P .
RESEARCH IN VETERINARY SCIENCE, 1996, 61 (01) :26-32
[15]   Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: Evaluation in models of acute inflammation [J].
Lees, P ;
McKellar, QA ;
Foot, R ;
Gettinby, G .
VETERINARY JOURNAL, 1998, 155 (03) :275-288
[16]  
Lefebvre HP, 1997, BIOPHARM DRUG DISPOS, V18, P79, DOI 10.1002/(SICI)1099-081X(199701)18:1<79::AID-BDD34>3.0.CO
[17]  
2-F
[18]   Selective feeding in the hawksbill turtle, an important predator in coral reef ecosystems [J].
León, YM ;
Bjorndal, KA .
MARINE ECOLOGY PROGRESS SERIES, 2002, 245 :249-258
[19]   Venipuncture techniques in chelonian species [J].
Mans, Christoph .
LAB ANIMAL, 2008, 37 (07) :303-304
[20]   Pharmacokinetics of ceftriaxone in Green sea turtles (Chelonia mydas) following intravenous and intramuscular administration at two dosages [J].
Mapongpeng, Roipim ;
Laovechprasit, Weerapong ;
Poapolathep, Amnart ;
Giorgi, Mario ;
Junchompoo, Chalatip ;
Sakulthaew, Chainarong ;
Jermnak, Usuma ;
Passadurak, Wanida ;
Poapolathep, Saranya .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2019, 42 (01) :104-110